Inozyme Pharma Newsroom

Inozyme Pharma Analyst Ratings

BenzingaJul 2 10:38 ET

Buy Rating Affirmed for Inozyme Pharma Amid Promising Drug Developments and Strong Revenue Projections

TipRanksJul 2 10:20 ET

Inozyme Pharma Analyst Ratings

BenzingaMay 30 10:54 ET

Inozyme Pharma Buy Rating Affirmed on Strong Trial Results and Robust Pipeline Prospects

TipRanksMay 8 06:20 ET

Needham Reiterates Buy on Inozyme Pharma, Maintains $23 Price Target

BenzingaMay 8 06:18 ET

Inozyme Pharma Analyst Ratings

BenzingaMay 8 06:17 ET

Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT) and Inozyme Pharma (INZY)

TipRanksMay 8 05:45 ET

Buy Rating on Inozyme Pharma Supported by Advancements in Lead Program and Promising Market Opportunities

TipRanksMay 8 05:35 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: Inozyme Pharma (INZY), Esperion (ESPR) and Madrigal Pharmaceuticals (MDGL)

TipRanksMay 8 05:35 ET

Inozyme Pharma Analyst Ratings

BenzingaApr 9 07:57 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: Inozyme Pharma (INZY), Zai Lab (ZLAB) and Idexx Laboratories (IDXX)

TipRanksApr 9 06:37 ET

Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX), Inozyme Pharma (INZY) and PTC Therapeutics (PTCT)

TipRanksApr 9 05:45 ET

Buy Rating for Inozyme Pharma Backed by Promising Clinical Progress and Unique Market Positioning of INZ-701

TipRanksMar 13 06:21 ET

Inozyme Pharma: Strong Buy Rating Amidst Promising Trial Developments and Market Underappreciation

TipRanksMar 12 12:50 ET

Inozyme Pharma Analyst Ratings

BenzingaMar 12 12:37 ET

Inozyme Pharma Analyst Ratings

BenzingaJan 30 10:49 ET

Needham Reiterates Buy on Inozyme Pharma, Maintains $23 Price Target

BenzingaNov 8, 2023 04:52 ET

Inozyme Pharma Analyst Ratings

BenzingaNov 8, 2023 04:51 ET

TD Cowen Reaffirms Their Buy Rating on Inozyme Pharma (INZY)

TipRanksNov 7, 2023 16:26 ET

Needham Reiterates Buy on Inozyme Pharma, Maintains $23 Price Target

BenzingaSep 27, 2023 06:31 ET